Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies

Bone Marrow Transplantation volume 54, pages 787–797 (2019)Cite this article

Subjects

Abstract

Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing number of management strategies ranging from observation through to stem cell transplantation. There has been an exciting expansion in novel agents to treat FL, but at present there is not a universally accepted standard of care in the relapse setting. Decision-making can be difficult for the clinician as there is a paucity of data to compare the various relapse therapies available. This review will discuss conventional therapy for relapsed FL, consider the use of novel agents and explore the role and timing of autologous and allogeneic stem cell transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:717–20.

    CAS  PubMed  Google Scholar 

  2. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.

    CAS  PubMed  Google Scholar 

  3. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–23.

    CAS  PubMed  Google Scholar 

  4. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51.

    CAS  PubMed  Google Scholar 

  5. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331–44.

    CAS  PubMed  Google Scholar 

  6. Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA Trial. J Clin Oncol. 2016;34:2575–82.

    CAS  PubMed  Google Scholar 

  7. Weide R, Hess G, Koppler H, Heymanns J, Thomalla J, Aldaoud A, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma. 2007;48:1299–306.

    CAS  PubMed  Google Scholar 

  8. Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol. 2009;2:14.

    PubMed  PubMed Central  Google Scholar 

  9. Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005;23:694–704.

    CAS  PubMed  Google Scholar 

  10. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010;116:106–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081–93.

    CAS  PubMed  Google Scholar 

  12. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–301.

    PubMed  Google Scholar 

  13. Sehn LH. Novel agents in follicular lymphoma: choosing the best target. Hematol Am Soc Hematol Educ Program. 2016;2016:284–92.

    Google Scholar 

  14. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111:5486–95.

    CAS  PubMed  Google Scholar 

  15. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119:3698–704.

    CAS  PubMed  Google Scholar 

  16. Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) with rituximab in patients with relapsed CD20+indolent B-cell non-hodgkin lymphoma: final analysis of the GAUSS Study. J Clin Oncol. 2015;33:3467–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Salles GA, Morschhauser F, Solal-Celigny P, Thieblemont C, Lamy T, Tilly H, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2920–6.

    CAS  PubMed  Google Scholar 

  18. Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122:1137–43.

    CAS  PubMed  Google Scholar 

  19. Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16:704–15.

    CAS  PubMed  Google Scholar 

  20. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085–93.

    CAS  PubMed  Google Scholar 

  21. Goy A, Forero A, Wagner-Johnston N, Christopher Ehmann W, Tsai M, Hatake K, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016;174:571–81.

    CAS  PubMed  Google Scholar 

  22. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–63.

    CAS  PubMed  Google Scholar 

  23. Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131:182–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.

    CAS  PubMed  Google Scholar 

  25. Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;125:242–8.

    CAS  PubMed  Google Scholar 

  26. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15:1019–26.

    CAS  PubMed  Google Scholar 

  27. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–18.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017;129:3037–9.

    CAS  PubMed  Google Scholar 

  29. Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O’Brien SM, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127:2411–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–78.

    CAS  PubMed  Google Scholar 

  32. Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaccaria A, et al. Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. Leuk Lymphoma. 2015;56:1671–6.

    CAS  PubMed  Google Scholar 

  33. Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33:3635–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013;121:1367–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77.

    CAS  PubMed  Google Scholar 

  36. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119:3940–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4:e176–e82.

    PubMed  PubMed Central  Google Scholar 

  39. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006;108:2540–4.

    CAS  PubMed  Google Scholar 

  40. Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113:995–1001.

    CAS  PubMed  Google Scholar 

  41. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667–74.

    CAS  PubMed  Google Scholar 

  42. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918–27.

    CAS  PubMed  Google Scholar 

  43. Kornacker M, Stumm J, Pott C, Dietrich S, Sussmilch S, Hensel M, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009;20:722–8.

    CAS  PubMed  Google Scholar 

  44. Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21:2324–31.

    CAS  PubMed  Google Scholar 

  45. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:1624–30.

    CAS  PubMed  Google Scholar 

  46. Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, Lopez-Guillermo A, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98:1014–21.

    PubMed  PubMed Central  Google Scholar 

  47. Bilmon IA, Ashton LJ, Le Marsney RE, Dodds AJ, O’Brien TA, Wilcox L, et al. Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study. Bone Marrow Transplant. 2014;49:691–8.

    PubMed  Google Scholar 

  48. El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M, et al. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Ann Oncol. 2014;25:2224–9.

    CAS  PubMed  Google Scholar 

  49. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325:1525–33.

    CAS  PubMed  Google Scholar 

  50. Gonzalez-Barca E, Fernandez de Sevilla A, Domingo-Claros A, Romagosa V, Martin-Henao GA, De Sanjose S, et al. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. Bone Marrow Transplant. 2000;26:1051–6.

    CAS  PubMed  Google Scholar 

  51. Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20:451–8.

    CAS  PubMed  Google Scholar 

  52. Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, et al. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015;168:824–34.

    CAS  PubMed  Google Scholar 

  53. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118:3419–25.

    CAS  PubMed  Google Scholar 

  54. Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood. 2014;124:3029–31.

    CAS  PubMed  Google Scholar 

  55. William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, et al. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. Biol Blood Marrow Transplant. 2014;20:536–42.

    CAS  PubMed  Google Scholar 

  56. Kim JW, Lee HJ, Yi HG, Kim BS, Bang SM, Kim JS, et al. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. Am J Hematol. 2012;87:479–83.

    CAS  PubMed  Google Scholar 

  57. Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant. 2010;45:1147–53.

    CAS  PubMed  Google Scholar 

  58. Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer . 2012;118:4706–14.

    CAS  PubMed  Google Scholar 

  59. Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, et al. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2017;52:1120–5.

    CAS  PubMed  Google Scholar 

  60. Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahe B, et al. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience. Ann Hematol. 2016;95:1287–93.

    CAS  PubMed  Google Scholar 

  61. van Besien K, Loberiza FR Jr., Bajorunaite R, Armitage JO, Bashey A, Burns LJ, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–9.

    PubMed  Google Scholar 

  62. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–78.

    CAS  PubMed  Google Scholar 

  63. Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY, et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2013;48:1409–14.

    CAS  PubMed  Google Scholar 

  64. Robinson SP, Boumendil A, Finel H, Schouten H, Ehninger G, Maertens J, et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party Of the EBMT. Ann Oncol. 2016.

  65. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;14:236–45.

    PubMed  PubMed Central  Google Scholar 

  66. Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, Mufti GJ, et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2009;147:719–28.

    PubMed  Google Scholar 

  67. Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol. 2008;141:235–43.

    PubMed  Google Scholar 

  68. Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018.

  69. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord–Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27:256–63.

    PubMed  Google Scholar 

  70. Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, et al. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009;15:214–22.

    PubMed  PubMed Central  Google Scholar 

  71. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016.

  72. Dietrich S, Finel H, Martinez C, Tischer J, Blaise D, Chevallier P, et al. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. Leukemia. 2016;30:2086–9.

    CAS  PubMed  Google Scholar 

  73. Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010;28:3695–700.

    PubMed  Google Scholar 

  74. Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant. 2011;17:1051–7.

    PubMed  Google Scholar 

  75. McNamara C, Davies J, Dyer M, Hoskin P, Illidge T, Lyttelton M, et al. Guidelines on the investigation and management of follicular lymphoma. Br J Haematol. 2012;156:446–67.

    PubMed  Google Scholar 

  76. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer . 2018;124:2541–51.

    CAS  PubMed  Google Scholar 

  78. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27:5404–9.

    CAS  PubMed  Google Scholar 

  79. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31:573–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325–33.

    CAS  PubMed  Google Scholar 

  82. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25:2554–9.

    PubMed  Google Scholar 

  83. Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26:3614–20.

    CAS  PubMed  Google Scholar 

  84. Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD, et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant. 2008;14:36–42.

    PubMed  Google Scholar 

  85. Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26:3166–75.

    CAS  PubMed  Google Scholar 

  86. Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011;96:1128–35.

    PubMed  PubMed Central  Google Scholar 

  87. Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer . 2013;119:3662–71.

    CAS  PubMed  Google Scholar 

  88. Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kroger NM, Hari PN, et al. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant. 2016;51:58–66.

    CAS  PubMed  Google Scholar 

  89. Jimenez-Ubieto A, Grande C, Caballero D, Yanez L, Novelli S, Hernandez-Garcia MT, et al. Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure. Biol Blood Marrow Transplant. 2017;23:1631–40.

    PubMed  Google Scholar 

  90. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:211–7.

    PubMed  Google Scholar 

  92. Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood. 2010;116:1795–802.

    CAS  PubMed  Google Scholar 

  93. Pinana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Diez-Martin JL, et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica. 2010;95:1176–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, Cutler CS, et al. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011;46:1503–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Khouri IF, Champlin RE. Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma. Cancer J. 2012;18:457–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Ono Y, Mori T, Kato J, Yamane A, Shimizu T, Kikuchi T, et al. Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma. Am J Hematol. 2012;87:929–31.

    PubMed  Google Scholar 

  97. Tada K, Kim SW, Asakura Y, Hiramoto N, Yakushijin K, Kurosawa S, et al. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma. Am J Hematol. 2012;87:770–5.

    PubMed  Google Scholar 

  98. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, et al. Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: a Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2016;22:1440–8.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Manchester Royal Infirmary, Manchester, UK

    Jane E. Norman

  2. Department Internal Medicine Hematology, University Hospital Maastricht, Maastricht, The Netherlands

    Harry C. Schouten

  3. Department of Haematology and Oncology, University of Heidelberg, Heidelberg, Germany

    Peter Dreger

  4. Department of Haematology, Bristol Oncology and Haematology Centre, Bristol, UK

    Stephen P. Robinson

Authors
  1. Jane E. Norman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harry C. Schouten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen P. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jane E. Norman.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Norman, J.E., Schouten, H.C., Dreger, P. et al. The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies. Bone Marrow Transplant 54, 787–797 (2019). https://doi.org/10.1038/s41409-018-0372-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0372-5

Search

Advanced search

Quick links